Exact Sciences (NASDAQ:EXAS) Given Outperform Rating at William Blair

William Blair reaffirmed their outperform rating on shares of Exact Sciences (NASDAQ:EXAS) in a report published on Thursday morning,RTT News reports.

EXAS has been the topic of a number of other reports. TD Cowen lifted their price objective on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Piper Sandler cut their price objective on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Jefferies Financial Group lifted their price objective on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group dropped their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Sanford C. Bernstein lifted their price target on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $72.06.

Exact Sciences Price Performance

Shares of Exact Sciences stock opened at $49.51 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The business’s 50 day simple moving average is $55.15 and its two-hundred day simple moving average is $60.03. The stock has a market capitalization of $9.16 billion, a P/E ratio of -42.32 and a beta of 1.24. Exact Sciences has a one year low of $40.62 and a one year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Analysts forecast that Exact Sciences will post -1.1 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EXAS. AMF Tjanstepension AB purchased a new position in shares of Exact Sciences in the third quarter worth $724,000. Creative Planning raised its stake in shares of Exact Sciences by 14.8% in the third quarter. Creative Planning now owns 38,060 shares of the medical research company’s stock worth $2,593,000 after purchasing an additional 4,906 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Exact Sciences by 61.0% in the third quarter. Blue Trust Inc. now owns 5,220 shares of the medical research company’s stock worth $356,000 after purchasing an additional 1,978 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in shares of Exact Sciences in the third quarter worth $569,000. Finally, Signaturefd LLC increased its position in Exact Sciences by 53.7% during the third quarter. Signaturefd LLC now owns 1,652 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 577 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.